- CLP Technology
- • The CLP(Complementary locking primer) is core MDx design technology of PCR Primer that is able to
enhance the high sensitivity and specificity of molecular diagnostics.
- • Possible to develop the Customized MDx Product according to needs.
-
Structure of CLP™Technology
Regulator is a palindromic structure against A region
-
Enhanced Sensitivity
-
Primer locking by CLP™Homo-dimer
- Formation of homo-dimer through complementary binding between the primers at low temperature
- No amplification before main PCR reaction because of the primer locking status.
- Can be reduced non-specific amplification
-
Enhanced Specificity
LiliF Diagnostics' CLP Technology is a unique patented technology for the design of primers for molecular
diagnostics. It is characterized by the formation of a self-dimer structure through the regulator region of the
primer before gene amplification. This induces complementary binding of the 5-terminal region of Primer
prior to PCR, blocking nonspecific nucleic acid amplification reactions at room temperature, inducing Hot Start
PCR reactions through primers, and amplifying target genes specifically. In addition, since the gene amplification
reaction is focused on amplifying target genes rather than being linked to nonspecific products, it increases
the detection sensitivity of target genes. In addition, the conventional PCR and real-time PCR reactions can
be used to uniformly adjust the annealing temperatures of different primer sets by adjusting regulators when
the Tm values of the primers are different due to various variations in multiplex detection. Technology
for multiplex design.
- Convergence Technology of...
- • Template Amplification : cDNA synthesis step
- • Signal Amplification : by Chimeric probe tech
Designed to maximize the detection sensitivity and reaction specificity of molecular diagnostics, MAT Technology
(Mobius Amplification Technology) is a technology that amplifies all stages from early DNA and RNA templates to
target nucleic acid amplification and detection. DNA-RNA hybrids by fluorescent chimeric probes can be bound
and decomposed only in target-specific sequences, and because they do not bind and decompose in non-specific
sequences, they show very high detection specificity compared to the existing 5 'Nuclease Assay.
Template amplification through the Cycling RT Reaction process, amplification of the target nucleic acid, and
hydrolysis of the continuous Chimeric probe maximize the signal amplification. Therefore, compared to the
conventional Real time PCR method, the detection limit is reached faster. It is an optimal platform technology that
can detect infectious agents quickly and sensitively.
- Maxime Technology
- • The nucleic acid amplification process which is core courses in MDx can be carried out easily and precisely.
- • All-in-one : All components for the molecular diagnosis is aliquot in each tube accurately,There is no deviation between the experimenters.
- • There is no risk about contamination by minimizing handling step and by individual packaging.
- • Possible to perform the economic diagnostic testing by providing all the components of MDx.
Real time Precise Validation of ALHP Process
Proven conformity of the product by real-time measurement in the process to check dispensing amount and variation.
| No. |
Fields |
Results |
| 1 |
Accuracy |
100% |
| 2 |
Error rate (Max / min) |
+ 3.7% / -3.8% |
| 3 |
CV % |
1.53% |
| 4 |
No. of Outliers |
0 |
| 5 |
CALL |
■ Pass □ Fail |
| 6 |
Acceptance criteria |
Within100 ±4% |
Very easy! Everybody can do MDx work professionally!
LiliF Diagnostics' Maxime Technology is a patented technology that maximizes ease of use so that anyone can
experience molecular diagnosis easily and accurately. However, not only ease of use, but also precise and clean
manufacturing and drying process helps to minimize the deviation or error of the experiment according to the user,
and can be supplied separately processed in test units to prevent the risk of cross contamination. . In addition, each
tube is shielded and packaged in strips to prevent external moisture or air from entering, and is provided to prevent
hydration or oxidation.
Z-SD Drymix as Sponge Cake
In addition to LiliF Diagnostics' Maxime Technology, the new Z-SD Drymix is a superior dehydrate processing
technology that puts all components for molecular diagnostics into a single tube and removes moisture within
the chamber (zero to less than 0.01%). Through this, the storage stability of the product can be increased 2 ~ 4 times
more than the existing one, and it is a new premix technology that can be used stably for a long time without
degrading the initial quality. Technology that can be reduced. In addition, instant rehydration reaction occurs
when adding distilled water and mold required for the reaction, minimizing the cumbersome mixing process
and thus reducing the variation between tests of molecular diagnosis. It can be used as an element technology
of various molecular diagnostics, which can be loaded into diagnostic materials and diagnostic products, and is
a drying technology that can be applied to the implementation of POCT-MDx devices through micro fluids.
RaLF Technology is a technology designed to allow anyone to easily and quickly detect the cause of a disease in the field.
The company designs and manufactures antigens and antibodies directly to produce nano-gold particles with high sensitivity,
specificity, and homogeneity, and conjugates them with conjugation conditions optimized for the physical and chemical
properties of colloidal gold and various antigens and antibodies. And clinically useful products.
- Antigen
Preparation
- Peptide Design
- Peptide Synthesis
- Peptide Conjugation
- Antigen
Immunization
- 6~8 Rounds of
Immunizations
- Antibody
Purification
- Antigen affinity purification
- Special affinity purification
- Antibody
Validation
- Antibody delivery
- Antibody validation
For RaLF Technology, antibodies have the greatest impact on product performance. Based on the primary structure from
the cDNA sequence, a peptide that is an immunogen was synthesized to produce more specific antibodies and applied
to the product. This technology enables the production of antibodies at desired sites, enabling the production of antibodies
specific for epitopes, allowing for rapid response to cross reactions and mutations. As a result, it is possible to increase
specificity and sensitivity in RDT diagnosis, which can lead to product development with high diagnostic and clinical usefulness.
